Mr. Ching Chung John CHOW (周靜忠) is a Non-executive Director of OrbusNeich.

Mr. Chow has around 39 years of experience in interventional cardiology. He worked in Cordis-Neich Limited in May 1984 and was promoted as the general manager in January 1991. Prior to joining our Group, he was appointed as the Asia Pacific regional marketing director of the Cordis franchise in Johnson & Johnson in June 1999. After his employment at Johnson & Johnson, Mr. Chow joined the Group in August 2000 and served as the head of sales and marketing for the Asia Pacific region from 2010 to 2015. Mr. Chow was appointed as the director of business development of the Group on May 17, 2006 and was served as the head of business development from September 2021 to September 2023.

Mr. Chow obtained his Bachelor of Arts degree from York University in Canada in June 1980.

Dr. Yi ZHOU (周伊) is a non-executive Director of OrbusNeich, primarily responsible for providing advice on the business development of OrbusNeich.

Dr. Zhou has around 16 years of research and working experience in the chemistry, pharmaceutical and biotechnology industries. He was an analyst in pharmaceutical industry at Shenzhen Capital Group Co., Ltd. from May 2012 to September 2017. Since October 2017, Dr. Zhou has served as the head of department of the health industry fund in Shenzhen Capital Group Co., Ltd. Dr. Zhou has been a non-executive director of Akeso, Inc., a company listed on the Main Board of the Stock Exchange (stock code: 9926), since November 2019, and was a director of Shenzhen YHLO Biotech Co., Ltd. (深圳市亞輝龍生物科技股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 688575), from December 2016 to December 2022.

Dr. Zhou obtained his Bachelor’s degree in chemistry from Hengyang Normal University in Hunan, the PRC in June 2003, his Master ’s degree in organic chemistry from Hunan Normal University in Hunan, the PRC in July 2007, and his Ph.D. degree in medicinal chemistry from Peking University in the PRC in June 2011.

Mr. Ting San Peter Lionel LEUNG (梁鼎新) is a non-executive Director of OrbusNeich.

Mr. Leung has over 37 years of experience in developing and managing projects on the Mainland China and overseas. He started his career as an assistant architect in 1985 and became a project manager in 1991. Since then, he assumed various management positions in Hong Kong listed property developers. He joined Hang Lung Properties Limited, a company listed on the Main Board of the Stock Exchange (stock code: 00101) in January 2014, and become their Director-Project Management from 2017 until his departure in May 2024. He joined Galaxy Entertainment Group Limited, a company listed on the Main Board of the Stock Exchange (stock code: 0027) in May 2024 as Executive Vice President Project Development.

Mr. Leung obtained a Postgraduate Diploma in Construction Project Management from The University of Hong Kong in July 1995, a Bachelor of Architecture degree and a Bachelor of Science (Architecture) degree from McGill University, Canada in June 1984 and June 1985, respectively. He is also a Registered Architect in Hong Kong, a member of the Hong Kong Institute of Architects and holds a PRC Class 1 Registered Architect Qualification. Mr. Leung is an executive committee member of the China Real Estate Chamber of Commerce Hong Kong and International Chapter since October 2020.

Mr. Yip Keung CHAN (陳業強) is an independent non-executive Director of OrbusNeich and is primarily responsible for supervising and providing independent judgment to our Board.

Mr. Chan has more than 18 years of experience in financial reporting, auditing, corporate finance, capital management and corporate governance. He started working in PricewaterhouseCoopers in September 2005 and was promoted as manager in October 2010. Mr. Chan was the finance manager of Mapletree Hong Kong Management Limited under Temasek of Singapore from November 2011 to April 2015, specialized in real estate investment trusts sector. He was the chief financial officer of the Pine Care Group Limited, (a company previously listed on the Stock Exchange with stock code 1989 and was delisted in February 2024) from April 2015 to October 2020 and is currently the chief executive officer and executive director of the aforementioned group. He was appointed by Chinachem Group as the Director of Elderly Care Services in November 2022.

Mr. Chan obtained his Bachelor of Business Administration degree from the Chinese University of Hong Kong in 2005 and masters’ degree in corporate governance from Hong Kong Polytechnic University in 2017. He is a certified public accountant in Hong Kong, a fellow of the Hong Kong Institute of Certified Public Accountant, and an associate member of the Hong Kong Institute of Chartered Secretaries and the Chartered Governance Institute.

Dr. Lai Fan Gloria TAM (譚麗芬) is an independent non-executive Director of OrbusNeich and is primarily responsible for supervising and providing independent judgment to our Board.

Dr. Tam has around 40 years of experience in the healthcare industry. She started working as a Medical and Health Officer in the Medical and Health Department, Hong Kong Government in January 1984 and became as Deputy Director of health in July 2007. She was also the Controller of Centre for Food Safety in Hong Kong from June 2012 to June 2017. She is the founder of 3 Srs Company (仨仁一人有限公司), a public health consultancy cum investment firm, since June 2020. Dr. Tam served as an independent non-executive director of Zhaoke Ophthalmology Limited, a company listed on the Main Board of the Stock Exchange (stock code: 6622), from April 2021 to April 2022. Dr. Tam has been an independent non-executive director of Arta TechFin Corporation Limited (formerly known as Freeman FinTech Corporation Limited), a company listed on the Main Board of the Stock Exchange (stock code: 279), since October 2021.

Dr. Tam obtained her Bachelor of Medicine and Bachelor of Surgery degrees from The University of Hong Kong in 1983 and Master of Medicine (Public Health) from the National University of Singapore in May 1993. She was elected as a Fellow of the Faculty of Public Health of the Royal College of Physicians, United Kingdom in February 2007.

Mr. Ka Keung LAU (樓家強), BBS, MH, JP, is an independent non-executive Director of OrbusNeich and is primarily responsible for supervising and providing independent judgment to our Board.

Mr. Lau has around 26 years of experience in business management. Mr. Lau held several positions in the Nameson Group from August 1999 to March 2013, including information technology manager, vice president, and executive director. From August 2015 to April 2018, Mr. Lau served as a non-executive director in Nameson Holdings Limited (南旋控股有限公司), a company listed on the Main Board of the Stock Exchange (stock code: 1982). Mr. Lau has served as an executive director and chief executive officer of Million Cities Holdings Limited (萬城控股有限公司) (“Million Cities”), a company listed on the Main Board of the Stock Exchange (stock code: 2892) since 2016, and has assumed various directorships in subsidiaries of Million Cities. Mr. Lau has been appointed as an independent non-executive director of Tianjin Development Holdings Limited, a company listed on the Main Board of the Stock Exchange (stock code: 882), since March 30, 2023.

Mr. Lau received his Bachelor’s degree from Manchester Metropolitan University, the United Kingdom in July 1997 and obtained his master’s degree in business administration from University of Leicester, the United Kingdom in July 2008. Mr. Lau has served as deputy to the 14th National People’s Congress (第十四屆全國人民代表大會), national committee member of the 13th Chinese People Political Consultative Conference in the PRC (中國人民政治協商會議第十三屆全國委員會), executive committee member of the 14th Tianjin Committee of Chinese People’ Political Consultative Conference (中國人民政治協商會議天津市第十四屆常務委員會) and Vice Chairman of Tianjin Federation of Industry and Commerce (天津市工商業聯合會). Mr. Lau is also the chairman of the 28th Hong Kong United Youth Association (香港青年聯會).